Vascular Biogenics Ltd. (NASDAQ:VBLT)’s share price was up 2.2% during mid-day trading on Wednesday . The company traded as high as $4.13 and last traded at $4.12, with a volume of 87,413 shares traded. The stock had previously closed at $4.03.

A number of equities research analysts recently weighed in on VBLT shares. Roth Capital reaffirmed a “buy” rating and set a $22.00 price objective on shares of Vascular Biogenics in a research report on Thursday, June 9th. HC Wainwright started coverage on Vascular Biogenics in a research report on Tuesday, June 28th. They set a “buy” rating and a $11.00 price objective on the stock. Chardan Capital reaffirmed a “buy” rating on shares of Vascular Biogenics in a research report on Tuesday, June 7th. Zacks Investment Research raised Vascular Biogenics from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a research report on Thursday, August 18th. Finally, Piper Jaffray Cos. reaffirmed a “buy” rating and set a $14.00 price objective on shares of Vascular Biogenics in a research report on Tuesday, June 7th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $13.67.

The company’s 50 day moving average price is $4.07 and its 200-day moving average price is $3.77. The firm’s market capitalization is $97.00 million.

Vascular Biogenics (NASDAQ:VBLT) last posted its earnings results on Monday, August 15th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.09. On average, equities analysts predict that Vascular Biogenics Ltd. will post ($0.64) EPS for the current year.

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.